Autoimmune Hepatitis
64
15
18
22
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.4%
6 terminated out of 64 trials
78.6%
-8.0% vs benchmark
11%
7 trials in Phase 3/4
23%
5 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 22 completed trials
Clinical Trials (64)
Thyroid Disorders in Pediatric Autoimmune Hepatitis
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Deciphering the Self-antigen Specific T Cell Signature of Autoimmune Liver Diseases
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis
TruGraf Liver Gene Expression Serial Test
PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach
Discrimination of DILI and AIH by Artificial Intelligence
Host-Diet-Gut Interaction Post Vegan Diet in Pediatric Autoimmune Hepatitis.
Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients
Belimumab in Autoimmune Hepatitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
Machine Learning for Prediction of Therapy Response in Autoimmune Hepatitis
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
Liver Cirrhosis Network Cohort Study
Repeatability and Reproducibility of Multiparametric MRI